|
Real-time Estimate
Cboe BZX
13:34:20 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 28.46 USD | -1.93% |
|
-5.70% | +2.71% |
| 09-01 | Beam Therapeutics Inc. Appoints Eric Foster as Chief Commercial Officer | CI |
| 08-19 | Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder | RE |
Company Valuation: Beam Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,327 | 2,692 | 2,159 | 1,974 | 2,736 | 2,900 | - | - |
| Change | - | -49.47% | -19.78% | -8.58% | 38.6% | 6% | - | - |
| Enterprise Value (EV) 1 | 4,367 | 1,613 | 969.4 | 1,974 | 2,441 | 1,983 | 1,678 | 2,054 |
| Change | - | -63.05% | -39.92% | 103.62% | 23.66% | -18.74% | -15.39% | 22.37% |
| P/E | -13.8x | -9.47x | -15.8x | -5.41x | -34.2x | -6.57x | -6.08x | -6.55x |
| PBR | 6.19x | 3.66x | 2.14x | 2.83x | 2.28x | 3.46x | 3.08x | 4.55x |
| PEG | - | 0.3x | 0.3x | -0x | 0.4x | -0x | -0.76x | 0.9x |
| Capitalization / Revenue | 103x | 44.2x | 5.72x | 31.1x | 19.6x | 59.7x | 46.2x | 23.5x |
| EV / Revenue | 84.2x | 26.5x | 2.57x | 31.1x | 17.5x | 40.8x | 26.7x | 16.7x |
| EV / EBITDA | -11.3x | -4.97x | -6.2x | -5.01x | -6.75x | -4.22x | -3.13x | -4x |
| EV / EBIT | -11.1x | -4.77x | -5.49x | -4.75x | -6.36x | -4.02x | -3.01x | -3.6x |
| EV / FCF | -38.6x | -61.1x | -5.3x | -5.54x | -6.78x | -13.1x | -9.28x | -11.1x |
| FCF Yield | -2.59% | -1.64% | -18.9% | -18% | -14.8% | -7.64% | -10.8% | -9.02% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 | -4.418 | -4.774 | -4.428 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 51.84 | 60.92 | 377.7 | 63.52 | 139.7 | 48.57 | 62.75 | 123.3 |
| EBITDA 1 | -385 | -324.3 | -156.5 | -393.6 | -361.4 | -470.2 | -536.4 | -513.8 |
| EBIT 1 | -392.5 | -338.5 | -176.5 | -415.6 | -383.7 | -493.7 | -557.8 | -569.9 |
| Net income 1 | -370.6 | -289.1 | -132.5 | -376.7 | -79.99 | -461.8 | -536.6 | -537.8 |
| Net Debt 1 | -960.4 | -1,078 | -1,190 | - | -294.9 | -916.4 | -1,222 | -846.2 |
| Reference price 2 | 79.69 | 39.11 | 27.22 | 24.80 | 27.72 | 29.02 | 29.02 | 29.02 |
| Nbr of stocks (in thousands) | 66,849 | 68,821 | 79,326 | 79,592 | 98,693 | 99,926 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/27/24 | 2/25/25 | 2/24/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.57x | 40.84x | -4.22x | -.--% | 2.9B | |
| 33.93x | 6.05x | 18x | 0.95% | 49.74B | |
| -21.45x | 254.03x | -23.17x | -.--% | 44.98B | |
| 33.27x | 3.24x | 13.96x | -.--% | 42.52B | |
| 46.98x | 5.43x | 29.72x | -.--% | 40.78B | |
| 28.55x | 8.63x | 21.82x | 0.4% | 32.89B | |
| 33.17x | 5.43x | 24.66x | -.--% | 16.28B | |
| 23.86x | 2.08x | 9x | 1.13% | 14.4B | |
| 75.53x | 3.99x | 15.46x | -.--% | 13.48B | |
| Average | 27.47x | 36.63x | 11.69x | 0.28% | 28.66B | |
| Weighted average by Cap. | 26.65x | 49.08x | 12.03x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BEAM Stock
- Valuation Beam Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
